After successful expansion into North America last year, Airfinity is proud to be opening a new office in Japan to provide a formal base for its activities across the APAC region.

Japan office launch

Airfinity further expands into APAC with launch of Japan office

GLP-1 receptor agonist-based compounds are the most common drug class in late stage clinical trials

23 anti-obesity drug clinical trials will reach primary completion within the next 3 months

Airfinity has launched an obesity intelligence solution dedicated to the breakthrough obesity treatments market. 

Obesity platformGIF

Airfinity launches obesity intelligence solution to forecast and simulate obesity related outcomes

Expired Paxlovid Doses

Paxlovid revenue

Airfinity analysis reveals over 1.5 million courses of Pfizer’s COVID-19 antiviral drug Paxlovid expired unused in European countries by the end of November. 

Stockpiles worth $1.1 billion of COVID-19 antiviral pill Paxlovid have expired in UK and Europe

Airfinity has been selected as the winning company in the healthcare category of the FT’s 2023 Tech Champions. The awards recognise the tech companies that have risen to the challenges and opportunities presented by new global risks, economic headwinds, geopolitical crises, and disruptive AI.

0F7A1677-Edit websize

Airfinity Named The Financial Times' Healthcare Tech Champion 2023

Airfinity is launching a biorisk surveillance solution that enables a country or region to better track, predict, and simulate incoming disease risks.

Airfinity upgrades global biorisk platform 

Airfinity is delighted to announce its inclusion in Bloomberg’s UK Startups to Watch 2023. The list features businesses that are truly innovative and unique, which are shaping the UK’s future.

Bloomberg

Airfinity named among Bloomberg’s UK Startups to Watch 2023

France faces massive increase in dengue cases by 2030

Wegovy table

Screenshot 2023-08-30 at 09.40.28

Screenshot 2023-08-30 at 11.26.40

Airfinity has revised its cost effectiveness analysis for Wegovy, increasing the cost of preventing one heart attack, stroke or cardio vascular death from $1.1m to $1.3m.

Your request has been sent!

Analysis & Insights

Airfinity further expands into APAC with launch of Japan office

More from Airfinity

In the News